Dr Reddy's Gains on Wegovy Plans

  Published 10 months ago

Dr Reddy’s rises 2.4% on plans to launch generic Wegovy in 87 nations; analysts boost earnings forecasts on growth outlook.

  • Targets early Semaglutide launch in Canada, global rollout before March 2026 patent expiry; low competition expected.
  • Jefferies, Goldman hike FY26–28 EPS forecasts; also sees growth from Abatacept IV launch in 2027.
  • Q1 profit slightly misses on U.S. pricing pressure; stock still down ~10% YTD despite 11.4% revenue growth.

You might like these

Oil Prices Fall on OPEC+ Supply Increase Talk

Balkrishna Industries Q4 Results & Outlook

Bajel Projects Stock Surges 5% on Mega Power Order

Tata Power Q1 Profit Up 6%, Solar Shines

Urban Company Shares Slide

JSW Cement IPO Subscribed 0.29x on Day 1

Tesla's First Self-Driving Model Y Arriving Soon

News that matters the most ⚡